Kezar Life Sciences (Kezar Life Sciences) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Kezar Life Sciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Kezar Life Sciences's Free Cash Flow for the three months ended in Dec. 2023 was $-18.98 Mil. Kezar Life Sciences's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Kezar Life Sciences's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Kezar Life Sciences's current FCF Yield % is -143.04%.

The historical rank and industry rank for Kezar Life Sciences's FCF Margin % or its related term are showing as below:

KZR' s FCF Margin % Range Over the Past 10 Years
Min: -1192.21 Med: -1192.21 Max: -1192.21
Current: -1192.21

During the past 8 years, the highest FCF Margin % of Kezar Life Sciences was -1192.21%. The lowest was -1192.21%. And the median was -1192.21%.

KZR's FCF Margin % is ranked worse than
77.89% of 1031 companies
in the Biotechnology industry
Industry Median: -148.24 vs KZR: -1192.21

Kezar Life Sciences FCF Margin % Historical Data

The historical data trend for Kezar Life Sciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kezar Life Sciences FCF Margin % Chart

Kezar Life Sciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-1,192.21

Kezar Life Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-290.59	-

Competitive Comparison of Kezar Life Sciences's FCF Margin %

For the Biotechnology subindustry, Kezar Life Sciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kezar Life Sciences's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kezar Life Sciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Kezar Life Sciences's FCF Margin % falls into.

Kezar Life Sciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Kezar Life Sciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-83.455	/	7
	=	-1,192.21 %

Kezar Life Sciences's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-18.981	/	0
	=	%

Kezar Life Sciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Kezar Life Sciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kezar Life Sciences (Kezar Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kezar Life Sciences Inc (NAS:KZR) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

2KZ:Germany 2KZ:Germany

Address

4000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.kezarlifesciences.com

Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as KZR-616, and the protein secretion program.

Executives

Morningside Venture Investments Ltd	10 percent owner	MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459
Nicholas Michael Mordwinkin	officer: Chief Business Officer	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger	director	1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Wallace Courtney	director	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Micki Klearman	director	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Equal Talent Investments Ltd	10 percent owner	THC MANAGEMENT SERVICES S.A.M. 2ND FLOOR, LE PRINCE DE GALLES 3-5 AVE DE CITRONNIE, MONTE CARLO O9 98000
Noreen Henig	officer: Chief Medical Officer	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
John Franklin Fowler	director, officer: CEO	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Christopher J. Kirk	director, officer: President and CSO	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Marc Belsky	officer: Chief Financial Officer	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Vassiliki Economides	officer: SVP, Strategy & External Aff.	C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Elizabeth Garner	director	101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Gp, Llc	10 percent owner	100 HIGH STREET, SUITE 1105, BOSTON DC 02110
Bay City Capital Llc	10 percent owner	750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111